Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648

Gastrointestinal Cancer

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649

Ann Oncol

Janjigian YY, Shitara K, Ajani JA, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, McCraith S, Hu N, Lei M, Zhang J, Moehler M

doi: 10.1016/j.annonc.2026.02.003

Genitourinary Cancer

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial

Ann Oncol

Choueiri TK, Albigès L, McDermott DF, Hammers HJ, Escudier B, Burotto M, Plimack ER, Porta C, George S, Powles T, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Castellano D, Grünwald V, Tomita Y, Rini BI, Jiang R, van Kooten Losio M, Lee CW, Tannir NM, Motzer RJ

doi: 10.1016/j.annonc.2026.02.017

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Oncol

Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G

doi: 10.1200/JCO-25-01328

Lung, Respiratory and Thoracic Cancer

Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial

J Thorac Oncol

Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC

doi: 10.1016/j.jtho.2026.103609

Lung, Respiratory and Thoracic Cancer

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Lung Cancer

Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, Çİl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC

doi: 10.1016/j.lungcan.2026.109302

Lung, Respiratory and Thoracic Cancer

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial

J Thorac Oncol

Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li Y, McIntyre DAG, Jia X, Perez J, Kaul M, Lowy I, Pouliot JF, Chua S, Kim E, Seebach F, Magnan H

doi: 10.1016/j.jtho.2026.103980

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

Genitourinary Cancer

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

Ann Oncol

Motzer RJ, Albiges L, Aguirre SAT, Kanesvaran R, Centkowski P, Reimers MA, Sade JP, Pouessel D, Biscaldi E, Esteban E, Arranz Arija JÁ, Tykodi SS, van Kooten Losio M, Dighe A, Ma H, Valmeekam V, Simmons A, Scheffold C, Andrianova S, Braun DA, Powles T, Choueiri TK

doi: 10.1016/j.annonc.2026.02.011

Skin Cancer

Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system

Eur J Cancer

Samaran Q, Bettuzzi T, Sbidian E

doi: 10.1016/j.ejca.2026.116585

Related content

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system